环丙沙星涂层鼻窦支架在临床前模型中的耐受性与药代动力学
研究分析环丙沙星涂层鼻窦支架(CSS,2 mg)的体外释放率及在16只兔上颌窦中的体内耐受性和药代动力学,术后1至3周处死。体外初始24小时突释后持续释放至14天;体内持续释放达3周,浓度>50 ng/mL,组织学与CT未见炎症、上皮溃疡、骨反应或黏膜水肿、浑浊。
要点
- CSS(2 mg)体外24小时突释后持续释放至14天。
- 兔上颌窦内环丙沙星持续释放达3周,浓度>50 ng/mL。
- 21天处死时组织学与CT未见炎症、上皮溃疡、骨反应或黏膜水肿、浑浊。
核心结论
- CSS在该临床前模型中安全,体外和体内分析均观察到持续释放。
- 作者认为涂有环丙沙星的创新支架设计可能为慢性鼻窦炎提供一种独特的治疗策略。
研究设计与样本
- 分析环丙沙星涂层鼻窦支架(CSS,2 mg,由可生物降解的聚-D/L-乳酸制成)的体外释放率及体内药物递送耐受性和药代动力学。
- CSS经背侧鼻窦切开术单侧置于16只兔的上颌窦内,动物在术后1至3周之间处死。
- 采用高效液相色谱法评估鼻窦组织和血浆中的环丙沙星浓度,并进行放射学和组织学评估。
主要发现
- 体外释放曲线中,最初24小时观察到突释,随后持续释放至14天时间点。
- 在兔模型中,环丙沙星从支架持续释放长达3周,剂量>50 ng/mL。
- 动物在21天处死时组织学检查未发现炎症、上皮溃疡或骨反应证据。
- 计算机断层扫描也未显示鼻窦黏膜水肿或浑浊迹象。
关键数值与推荐
- CSS载药量为2 mg。
- 体外突释发生在最初24小时,持续释放至14天时间点。
- 兔体内环丙沙星持续释放长达3周,浓度>50 ng/mL。
- 组织学和CT评估在21天处死时进行。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Chronic rhinosinusitis (CRS) is often associated with persistent bacterial infection despite the use of systemic antibiotics. Topically administered antibiotics are an alternative strategy, but require effective local concentrations, prolonged mucosal contact time, minor systemic absorption, and minimal depletion. The objectives of the current study were to analyze the in vitro release rate and in vivo drug delivery tolerance and pharmacokinetics of a ciprofloxacin-coated sinus stent (CSS). METHODS: The CSS (2 mg) was created from biodegradable poly-D/L-lactic acid. After analyzing in vitro release profile, CSSs were placed unilaterally in maxillary sinuses of 16 rabbits via dorsal sinusotomy. Animals were euthanized between 1 and 3 weeks postoperatively. Ciprofloxacin concentrations in the sinus tissue and plasmas were assessed using high-performance liquid chromatography. Radiological and histological evaluations were performed. RESULTS: In the in vitro release profile, an initial burst release was observed over the first 24 hours, followed by sustained release through the 14-day time point. In the rabbit model, ciprofloxacin was continuously released from the stent up to 3 weeks at doses >50 ng/mL. Histologic examination found no evidence of inflammation, epithelial ulceration, or bony reaction upon euthanization of the animals at 21 days. Computed tomography also demonstrated no signs of mucosal edema or opacification in the sinus. CONCLUSION: The CSS was safe in this preclinical model and sustained release was observed in both the in vitro and in vivo analyses. The innovative stent design coated with ciprofloxacin may provide a unique therapeutic strategy for chronic rhinosinusitis (CRS).
引用
- Cho DY, Hoffman K, Skinner D, et al. Tolerance and pharmacokinetics of a ciprofloxacin-coated sinus stent in a preclinical model. Int Forum Allergy Rhinol. 2016. PMID: 27992118. doi:10.1002/alr.21892
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。